BTZ043 Racemate is primarily used in the research and development of new treatments for tuberculosis (TB), particularly multidrug-resistant strains. It acts as a potent inhibitor of the DprE1 enzyme, which is essential for the biosynthesis of the mycobacterial cell wall. By targeting this specific pathway, BTZ043 disrupts the structural integrity of Mycobacterium tuberculosis, leading to bacterial death. Its high potency makes it a valuable lead compound in anti-TB drug discovery. Researchers use BTZ043 Racemate to study structure-activity relationships and to develop optimized derivatives with improved pharmacokinetic and safety profiles. It is not used clinically but serves as a critical tool in preclinical studies aimed at combating drug-resistant TB.